Cargando…

Injectable Disease Modifying Agents in Multiple Sclerosis: Pattern of Medication Use and Clinical Effectiveness

The objective of this study was to assess long-term use, adherence and efficacy of injectable disease modifying agents (DMAs). Multiple Sclerosis (MS) patients diagnosed during 2002-2010 with early treatment start and at least one year in first choice medication were included in a large university d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Järvinen, Elina, Holmberg, Markus, Sumelahti, Marja-Liisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066104/ https://www.ncbi.nlm.nih.gov/pubmed/27761226 http://dx.doi.org/10.4081/ni.2016.6513

Ejemplares similares

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
por: Järvinen, Elina, et al.
Publicado: (2019)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Increased Female MS Incidence and Differences in Gender-Specific Risk in Medium- and High-Risk Regions in Finland from 1981–2010
por: Holmberg, Markus, et al.
Publicado: (2013)

Increasing Incidence in Relapsing-Remitting MS and High Rates among Young Women in Finland: A Thirty-Year Follow-Up
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2014)

Diffusion tensor imaging and disability progression in multiple sclerosis: A 4‐year follow‐up study
por: Kolasa, Marcin, et al.
Publicado: (2018)

Medical students’ experience of emotions and success in neurological studies – What do they tell us?
por: Ansakorpi, Hanna, et al.
Publicado: (2017)

Disease Modifying Agents for Multiple Sclerosis
por: Hilas, Olga, et al.
Publicado: (2010)

Disease-modifying agents in multiple sclerosis
por: Coyle, P. K.
Publicado: (2009)

Comparative Adherence Trajectories of Oral Fingolimod and Injectable Disease Modifying Agents in Multiple Sclerosis
por: Earla, Jagadeswara R, et al.
Publicado: (2020)

Multiple Sclerosis: Overview of Disease-Modifying Agents
por: Finkelsztejn, Alessandro
Publicado: (2014)

Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
por: Earla, Jagadeswara Rao, et al.
Publicado: (2021)

Assessment of treatment patterns associated with injectable disease-modifying therapy among relapsing–remitting multiple sclerosis patients
por: Nicholas, J, et al.
Publicado: (2017)

Efficacy and tolerability of oral versus injectable disease-modifying therapies for multiple sclerosis in clinical practice
por: Longbrake, Erin E, et al.
Publicado: (2016)

Perspectives and experiences of Dutch multiple sclerosis patients and multiple sclerosis-specialized neurologists on injectable disease-modifying treatment
por: Visser, Leo H, et al.
Publicado: (2016)

Stroke and cardiovascular risk factors among working-aged Finnish migraineurs
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2021)

Disease-modifying therapy prescription patterns in people with multiple sclerosis by age
por: Zhang, Yinan, et al.
Publicado: (2021)

My Migraine Voice survey: disease impact on healthcare resource utilization, personal and working life in Finland
por: Sumelahti, Marja-Liisa, et al.
Publicado: (2020)

Disease-modifying treatments for multiple sclerosis – a review of approved medications
por: Torkildsen, Ø, et al.
Publicado: (2016)

Disease Modifying Therapy in Multiple Sclerosis
por: Williams, U. E., et al.
Publicado: (2014)

Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study)
por: Fernández, Oscar, et al.
Publicado: (2017)

Oral Disease-Modifying Therapies for Multiple Sclerosis
por: Kim, Woojun, et al.
Publicado: (2015)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Multiple Sclerosis, Disease-Modifying Therapies, and Infections
por: Langer-Gould, Annette M., et al.
Publicado: (2023)

Adherence to Disease-Modifying Therapies for Multiple Sclerosis
por: Higuera, Lucas, et al.
Publicado: (2016)

Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study
por: Järvinen, Elina, et al.
Publicado: (2017)

The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
por: Beer, Karsten, et al.
Publicado: (2011)

Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
por: Braune, Stefan, et al.
Publicado: (2015)

Quality of life among injectable and oral disease-modifying therapy users in the Pacific Northwest Multiple Sclerosis Registry
por: Stuchiner, Tamela, et al.
Publicado: (2020)

Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy
por: Bowen, James, et al.
Publicado: (2020)

Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis
por: Zaheer, Reemal, et al.
Publicado: (2023)

Immunological Mechanism of Action and Clinical Profile of Disease-Modifying Treatments in Multiple Sclerosis
por: Du Pasquier, Renaud A., et al.
Publicado: (2014)

Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population
por: Molazadeh, Negar, et al.
Publicado: (2023)

Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review
por: Nazareth, Tara, et al.
Publicado: (2016)

New oral disease-modifying therapies for multiple sclerosis
por: Bagert, Bridget A, et al.
Publicado: (2009)

Disease-modifying therapies in relapsing–remitting multiple sclerosis
por: González-Andrade, Fabricio, et al.
Publicado: (2010)

Adherence to disease-modifying therapies in patients with multiple sclerosis
por: Kołtuniuk, Aleksandra, et al.
Publicado: (2018)

Disease-modifying therapies in multiple sclerosis in Latin America
por: Skromne-Eisenberg, Eli, et al.
Publicado: (2017)

Safety of Newer Disease Modifying Therapies in Multiple Sclerosis
por: Jalkh, Georges, et al.
Publicado: (2020)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug
por: Munsell, Michael, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cv1q9hlckh1dtbpoab23v1qiep